There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Vertex (VERX – Research Report) and Cabaletta Bio (CABA – Research Report) with bullish sentiments.
Vertex (VERX)
Goldman Sachs analyst Adam Hotchkiss maintained a Buy rating on Vertex today and set a price target of $33.00. The company’s shares closed last Thursday at $27.11.
According to TipRanks.com, Hotchkiss is a 3-star analyst with an average return of
Currently, the analyst consensus on Vertex is a Strong Buy with an average price target of $28.50, which is a 25.9% upside from current levels. In a report released today, Needham also maintained a Buy rating on the stock with a $35.00 price target.
See Insiders’ Hot Stocks on TipRanks >>
Cabaletta Bio (CABA)
TD Cowen analyst Phil Nadeau maintained a Buy rating on Cabaletta Bio today. The company’s shares closed last Thursday at $17.52, close to its 52-week high of $19.34.
According to TipRanks.com, Nadeau is a 5-star analyst with an average return of
Currently, the analyst consensus on Cabaletta Bio is a Strong Buy with an average price target of $29.50, implying a 70.4% upside from current levels. In a report issued on November 7, H.C. Wainwright also maintained a Buy rating on the stock with a $17.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on VERX:
